The five-year grant will support a team of researchers that is trying to demonstrate how a novel bile salt can prevent C. diff spore germination.
“The infection form of C. difficile is the spore, a resistant structure that can survive on hospital surfaces for extended periods,” said Steven Firestine, PhD, associate professor of pharmaceutical sciences at Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences and member of the research team. “Our focus is on the synthesis and evaluation of compounds that prevent the conversion of the spore into growing bacterium. The lead agent has shown remarkable properties in the prevention of this disease, but there are still some issues related to its strength and stability that we need to address.”
This study has the potential to decrease the spread of C. diff infections, which occur frequently in healthcare settings and can have a mortality rate greater than 2.5 percent.
More articles on infection prevention:
Using LEDs to disinfect hospitals? Mount Sinai in NYC tests the technology
Patient safety tool: AHA, AMA, APIC flu resources
Ebola fighters are TIME’s person of the year
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.